• Source: Scopus
20032021

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

My research is focused on pre-clinical studies and early phase clinical trials evaluating molecular therapeutic agents, including IGF-IR antibody and Chk1 inhibitors, for the treatment of breast cancer. Breast cancer cell lines and xenograft models as well as patients’ specimens are used to evaluate the mechanisms of action of these agents and to develop potential predictors of treatment response. A multi-center phase I/II study of IMC-A12 (ImClone Inc.), an IGF-IR antibody, in combination with temsirolimus in patients with metastatic breast cancer has been approved by NCI/CTEP to evaluate the efficacy and tolerability for the combined targeting of IGF-IR and mTOR. In collaboration with Drs. Helen Piwnica-Worms and Paula Fracasso, we are conducting an exploratory study of UCN-01, a Chk1 inhibitor, in combination with irinotecan in patients with triple negative breast cancer (negative for estrogen receptor, progesterone receptor and HER2 overexpression).

Areas of Clinical Interest

Cancer, breast cancer

Fingerprint

Dive into the research topics where Cynthia Ma is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 23 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.
If you made any changes in Pure these will be visible here soon.